Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  AstraZeneca PLC    AZN   GB0009895292


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

AstraZeneca : U.S. to ship 85% fewer J&J vaccine doses to states next week

04/08/2021 | 02:08pm EDT

April 8 (Reuters) - The U.S. government will allocate nearly 85% fewer Johnson & Johnson COVID-19 vaccine doses to states next week, according to data from the Centers for Disease Control and Prevention (CDC), due to uneven production related in part to problems at a Baltimore manufacturing plant.

Allocations will fall to 785,500 doses from 4.95 million doses this week. The data does not include a federal retail pharmacy program.

An official from the U.S. Department of Health and Human Services (HHS), who did not wish to be named, told Reuters that J&J released about 1.5 million doses to the U.S. government this week, compared with about 11 million doses last week. The allocation and distribution of COVID-19 vaccines is handled by the federal government.

HHS expects J&J's supply to be uneven, the official said, but added that the company had promised it was on track to meet its commitment of delivering close to 100 million doses by the end of May.

J&J did not respond to requests for comment.

J&J last month said it had delivered enough of its one-dose vaccine by the end of March to enable full vaccination of more than 20 million people. The company said it would be able to deliver an additional 24 million doses through April.

A New York Times report last week said that workers at an Emergent BioSolutions facility in Baltimore contracted to make both the AstraZeneca Plc and J&J vaccines, mixed up ingredients of the two shots, ruining 15 million J&J doses.

The Baltimore facility has not been authorized by the U.S. Food and Drug Administration, and a federal health official told Reuters last week that no vaccines produced at the plant had gone into arms.

A report from last year posted by the FDA on Thursday showed that inspectors had flagged several issues at the plant in April 2020, before the company began making COVID-19 vaccines, including inadequate controls to prevent contamination, training problems, and other quality control issues.

"We have worked and continue to work closely with the federal government in support of the COVID response," Emergent spokesman Matt Hartwig said in an email. "These FDA observations were addressed and reviewed in detail with FDA during their recent site visits in September 2020 and February 2021."

According to CDC data, California receives largest allotment of the J&J vaccine, followed by Texas and Florida. The vaccine allocation for California will be down by about 88%, with the state set to receive a maximum of 67,600 doses next week.

A California health official told Reuters that the state's allocation will fall further to 22,400 doses in the week starting April 18.

(Reporting by Shubham Kalia and Aakriti Bhalla in Bengaluru; Aadditional reporting by Ankur Banerjee in Bangaluru and Michael Erman in New York; Editing by Simon Cameron-Moore and Bill Berkrot)

© Reuters 2021
All news about ASTRAZENECA PLC
03:55pASTRAZENECA  : India approves Russia's Sputnik V COVID-19 vaccine
12:29pTHE LATEST : CDC head warns against surging shots to Michigan
12:08pLONDON STOCK EXCHANGE : FTSE 100 ends lower as miners track lower metal prices; ..
10:25aASTRAZENECA  : Argus Research Downgrades AstraZeneca to Hold From Buy
09:35aASTRAZENECA  : Ireland set to restrict use of AstraZeneca vaccine -RTE
09:33aAustralia Expects Big Delays to Vaccine Rollout
09:02aBulgarian PM reveals price for EU's new vaccine contract with Pfizer
08:35aASTRAZENECA  : Brazil, Mexico, Philippines among those due to get Pfizer shots f..
08:00aSpain expects first batch of single-dose Janssen shot within 48 hours
07:26aEUROPE ECONOMICS : Action Economics on The UK Week Ahead; COVID-19 Vaccine Rollo..
More news
Financials (USD)
Sales 2021 30 893 M - -
Net income 2021 4 586 M - -
Net Debt 2021 14 367 M - -
P/E ratio 2021 27,7x
Yield 2021 2,86%
Capitalization 131 B 131 B -
EV / Sales 2021 4,71x
EV / Sales 2022 4,06x
Nbr of Employees 76 100
Free-Float 95,8%
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 25
Average target price 130,05 $
Last Close Price 99,88 $
Spread / Highest target 66,2%
Spread / Average Target 30,2%
Spread / Lowest Target -5,71%
EPS Revisions
Managers and Directors
Pascal Soriot Chief Executive Officer & Executive Director
Marc Pierre Jean Dunoyer Chief Financial Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Menelas N. Pangalos EVP-Biopharmaceuticals Research & Development
Pam P. Cheng Executive VP-Operations & Information Technology
Sector and Competitors
1st jan.Capitalization (M$)
ASTRAZENECA PLC-0.51%131 272
JOHNSON & JOHNSON2.46%424 524
ROCHE HOLDING AG0.21%288 043
PFIZER, INC.-0.57%204 161
NOVARTIS AG-3.29%197 172
MERCK & CO., INC.-6.71%193 164